ArticleThe Lancet. Microbe2022

Is low-dose tafenoquine combined with dihydroartemisinin-piperaquine a potential risk factor for Plasmodium vivax resistance to 8-aminoquinolines?

Temi LampejoPubMed ↗Publisher ↗

No numbers read from the abstract.